FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:1260-1261 September 16, 2004 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Lynch, T. J. PubMed Citation

To the Editor: The important study by Dr. Lynch and colleagues (May 20 issue)¹ suggests that specific mutations in the epidermal growth factor receptor (EGFR) characterize a subgroup of non–small-cell lung cancers that may be highly responsive to gefitinib therapy. Do these mutations predict a greater sensitivity to chemotherapy as well? The overall objective response rate to first-line combination chemotherapy for metastatic non–small-cell lung cancer is about 20 percent.² Only tumors from a small cohort of patients who had a response to gefitinib were studied for the specific mutations, but all patients except one had also received prior chemotherapy. Although . . . [Full Text of this Article]

This article has been cited by other articles:

• Broniscer, A., Baker, S. J., Stewart, C. F., Merchant, T. E., Laningham, F. H., Schaiquevich, P., Kocak, M., Morris, E. B., Endersby, R., Ellison, D. W., Gajjar, A. (2009). Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma. Clin. Cancer Res. 15: 701-707 [Abstract] [Full Text]  
• Brandes, A. A., Franceschi, E., Tosoni, A., Hegi, M. E., Stupp, R. (2008). Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments. Clin. Cancer Res. 14: 957-960 [Abstract] [Full Text]  
• Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H.Y., Chute, D. J., Riggs, B. L., Horvath, S., Liau, L. M., Cavenee, W. K., Rao, P. N., Beroukhim, R., Peck, T. C., Lee, J. C., Sellers, W. R., Stokoe, D., Prados, M., Cloughesy, T. F., Sawyers, C. L., Mischel, P. S. (2005). Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors.. NEJM 353: 2012-2024 [Abstract] [Full Text]  
• Lassman, A. B., Rossi, M. R., Razier, J. R., Abrey, L. E., Lieberman, F. S., Grefe, C. N., Lamborn, K., Pao, W., Shih, A. H., Kuhn, J. G., Wilson, R., Nowak, N. J., Cowell, J. K., DeAngelis, L. M., Wen, P., Gilbert, M. R., Chang, S., Yung, W.A., Prados, M., Holland, E. C. (2005). Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01. Clin. Cancer Res. 11: 7841-7850 [Abstract] [Full Text]  
• Dicker, A. P., Rodeck, U. (2005). Predicting the Future From Trials of the Past: Epidermal Growth Factor Receptor Expression and Outcome of Fractionated Radiation Therapy Trials. JCO 23: 5437-5439 [Full Text]  
• Marie, Y., Carpentier, A. F., Omuro, A.M.P., Sanson, M., Thillet, J., Hoang-Xuan, K., Delattre, J. -Y. (2005). EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64: 1444-1445 [Abstract] [Full Text]  
• Goudar, R. K., Shi, Q., Hjelmeland, M. D., Keir, S. T., McLendon, R. E., Wikstrand, C. J., Reese, E. D., Conrad, C. A., Traxler, P., Lane, H. A., Reardon, D. A., Cavenee, W. K., Wang, X.-F., Bigner, D. D., Friedman, H. S., Rich, J. N. (2005). Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Molecular Cancer Therapeutics 4: 101-112 [Abstract] [Full Text]